GlaxoSmithKline (Licensor)Renaissance Acquisition Holdings (Licensee)
GlaxoSmithKline granted Renaissance rights to market six approved dermatology drugs and three formulations of Zovirax acyclovir in the U.S.
Stiefel (Seller)GlaxoSmithKline (Buyer)
GlaxoSmithKline acquiring dermatology company Stiefel for $2.9 billion in cash and $300 million in milestones
Set Email Alert